Saba Capital details 4.95% stake in abrdn Life Sciences (HQL)

Rhea-AI Filing Summary

Saba Capital Management and related parties filed Amendment No. 12 to their Schedule 13D on abrdn Life Sciences Investors, updating their disclosure of a significant position in the fund’s common shares.

The reporting group now reports beneficial ownership of 1,464,161 common shares, representing 4.95% of the outstanding shares based on 29,598,692 shares outstanding as of September 30, 2025. The filing states that approximately $19,201,394 was paid in total to acquire these shares, with purchases funded by investor capital, related appreciation, and ordinary-course margin borrowings.

Recent activity consisted of open-market transactions between February 11, 2026 and February 19, 2026, as detailed in Schedule A to the amendment. The filers indicate no specific corporate action or change of control purpose for the investment and report no special contracts or arrangements regarding the issuer’s securities.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 12)

abrdn Life Sciences Investors

(Name of Issuer)

Common Shares, $0.01 par value

(Title of Class of Securities)

87911K100

(CUSIP Number)

Saba Capital Management, L.P.
405 Lexington Avenue, 58th Floor, Attention: Michael D'Angelo
New York, NY, 10174
(212) 542-4635

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 87911K100

1

Name of reporting person

Saba Capital Management, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,464,161.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,464,161.00

11

Aggregate amount beneficially owned by each reporting person

1,464,161.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.95 %

14

Type of Reporting Person (See Instructions)

PN, IA

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 29,598,692 shares of common stock outstanding as of 9/30/25, as disclosed in the company's N-CSR filed 12/8/25.

SCHEDULE 13D

CUSIP No. 87911K100

1

Name of reporting person

Boaz R. Weinstein

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,464,161.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,464,161.00

11

Aggregate amount beneficially owned by each reporting person

1,464,161.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.95 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 29,598,692 shares of common stock outstanding as of 9/30/25, as disclosed in the company's N-CSR filed 12/8/25.

SCHEDULE 13D

CUSIP No. 87911K100

1

Name of reporting person

Saba Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,464,161.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,464,161.00

11

Aggregate amount beneficially owned by each reporting person

1,464,161.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.95 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 29,598,692 shares of common stock outstanding as of 9/30/25, as disclosed in the company's N-CSR filed 12/8/25.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Shares, $0.01 par value
(b)	Name of Issuer: abrdn Life Sciences Investors
(c)	Address of Issuer's Principal Executive Offices: 1900 Market Street, Philadelphia, PENNSYLVANIA , 19103.
Item 1 Comment: This Amendment No. 12 amends Items 3, 5, and 7.
Item 2.	Identity and Background
(a)	This Schedule 13D/A is being jointly filed by: (i) Saba Capital Management, L.P., a Delaware limited partnership ("Saba Capital"); (ii) Saba Capital Management GP, LLC, a Delaware limited liability company ("Saba GP"); and (iii) Mr. Boaz R. Weinstein ("Mr. Weinstein"), (together, the "Reporting Persons"). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Sections 13 of the Securities Exchange Act of 1934, the beneficial owner of the Common Shares reported herein.
(b)	The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174.
(c)	The principal business of: (i) Saba Capital is to serve as investment manager to private and public investment funds and/or accounts, (ii) Saba GP is to serve as general partner of the Saba Capital and other affiliated entities, and (iii) Mr. Weinstein, an individual, is managing member of the general partner of Saba Capital and other affiliated entities.
(d)	The Reporting Persons have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	The Reporting Persons have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
(f)	Saba Capital is organized as a limited partnership under the laws of the State of Delaware. Saba GP is organized as a limited liability company under the laws of the State of Delaware. Mr. Weinstein is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	Funds for the purchase of the Common Shares were derived from the subscription proceeds from investors and the capital appreciation thereon and margin account borrowings made in the ordinary course of business. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Shares reported herein. A total of approximately $19,201,394 was paid to acquire the Common Shares reported herein.
Item 4.	Purpose of Transaction
	Not Applicable.
Item 5.	Interest in Securities of the Issuer
(a)	See the Reporting Persons section of this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 29,598,692 shares of common stock outstanding as of 9/30/25, as disclosed in the company's N-CSR filed 12/8/25.
(b)	See the Reporting Persons section of this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	The transactions in the Common Shares effected from the filing of the Schedule 13D/A on 2/11/26 by the Reporting Persons to 2/19/26, the date of the event which required filing of this Schedule 13D/A, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference.
(d)	The funds and accounts advised by Saba Capital have the right to receive the dividends and proceeds of sales from the Common Shares.
(e)	Feb-19-2026
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 8 - Schedule A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Saba Capital Management, L.P.

Signature:	/s/ Michael D'Angelo
Name/Title:	General Counsel
Date:	02/23/2026

Boaz R. Weinstein

Signature:	/s/ Michael D'Angelo
Name/Title:	Authorized Signatory
Date:	02/23/2026

Saba Capital Management GP, LLC

Signature:	/s/ Michael D'Angelo
Name/Title:	Attorney-in-fact*
Date:	02/23/2026

Comments accompanying signature:

Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823

FAQ

What stake in HQL does Saba Capital report in this Schedule 13D/A?

Saba Capital and related parties report beneficial ownership of 1,464,161 common shares of abrdn Life Sciences Investors, representing 4.95% of the outstanding common shares based on 29,598,692 shares reported as of September 30, 2025.

How much did Saba Capital pay to acquire its HQL shares?

The filing states that Saba-related funds paid a total of about $19,201,394 to acquire the reported common shares. Funds came from investor subscriptions, capital appreciation on those investments, and ordinary-course margin borrowings secured by positions in the margin accounts.

Did Saba Capital use margin to buy its HQL position?

Yes. The amendment explains that purchases were funded partly through margin account borrowings in the ordinary course of business. Because other securities are also held in these accounts, the filers state it is not possible to isolate the exact margin used for HQL purchases.

What period of HQL trading activity does this Schedule 13D/A cover?

The amendment refers to transactions from the prior amendment filed on February 11, 2026 through February 19, 2026, the event date requiring this filing. All transactions in that period were executed in the open market and are detailed in Schedule A.

Does Saba Capital state any specific plans or purposes for its HQL investment?

The document lists the purpose of transaction as “Not Applicable”. It does not outline specific plans such as seeking board changes or corporate actions, and focuses instead on updating ownership levels and transaction details for the common shares.

Who are the reporting persons in this HQL Schedule 13D/A filing?

The filing is jointly made by Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein. Saba Capital acts as investment manager, Saba GP as its general partner, and Mr. Weinstein is managing member of the general partner.